Thus, compounds that stimulate both PPARα and PPARγ (dual PPARα/γ agonists) should additively improve both lipid and glucose abnormalities in animal models and human subjects with insulin resistance (IR) and/or type 2 diabetes (T2DM). Here, PPARG is linked to type 2 diabetes mellitus.